338 related articles for article (PubMed ID: 32534142)
1. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
[TBL] [Abstract][Full Text] [Related]
3. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
Thabit AK; Crandon JL; Nicolau DP
Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
[TBL] [Abstract][Full Text] [Related]
5. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
7. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of atypical pathogens in patients hospitalized with community-acquired respiratory infection.
Schneeberger PM; Dorigo-Zetsma JW; van der Zee A; van Bon M; van Opstal JL
Scand J Infect Dis; 2004; 36(4):269-73. PubMed ID: 15198183
[TBL] [Abstract][Full Text] [Related]
9. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia.
Bassetti M; Melchio M; Giacobbe DR
Expert Rev Anti Infect Ther; 2022 May; 20(5):649-656. PubMed ID: 34913817
[TBL] [Abstract][Full Text] [Related]
10. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
Horcajada JP; Salata RA; Álvarez-Sala R; Nitu FM; Lawrence L; Quintas M; Cheng CY; Cammarata S;
Open Forum Infect Dis; 2020 Jan; 7(1):ofz514. PubMed ID: 31988972
[TBL] [Abstract][Full Text] [Related]
12. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
Lodise TP; Tillotson GS; Spargo A; Bozkaya D; Massey J
Clin Drug Investig; 2020 Oct; 40(10):961-971. PubMed ID: 32651832
[TBL] [Abstract][Full Text] [Related]
13. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
14. The atypical pneumonias: clinical diagnosis and importance.
Cunha BA
Clin Microbiol Infect; 2006 May; 12 Suppl 3():12-24. PubMed ID: 16669925
[TBL] [Abstract][Full Text] [Related]
15. [The role of atypical pathogen: Mycoplasma pneumoniae and Chlamydia pneumoniae in the acute respiratory infection in childhood].
Ouchi K
Jpn J Antibiot; 2000 Jun; 53 Suppl B():13-21. PubMed ID: 12572086
[TBL] [Abstract][Full Text] [Related]
16. Delafloxacin as a treatment option for community-acquired pneumonia infection.
Nascimento-Carvalho CM
Expert Opin Pharmacother; 2021 Oct; 22(15):1975-1982. PubMed ID: 34346823
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
[TBL] [Abstract][Full Text] [Related]
18. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Tang HJ; Wang JH; Lai CC
Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
[TBL] [Abstract][Full Text] [Related]
19. A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Gómez-Zorrilla S; Sendra E; Horcajada JP
Expert Rev Clin Pharmacol; 2022 Jun; 15(6):671-688. PubMed ID: 35838033
[TBL] [Abstract][Full Text] [Related]
20. Etiology and efficacy of anti-microbial treatment for community-acquired pneumonia in adults requiring hospital admission in Ukraine.
Kaidashev I; Lavrenko A; Baranovskaya T; Blazhko V; Digtiar N; Dziublyk O; Gerasymenko N; Iashyna L; Kryvetskyi V; Kuryk L; Rodionova V; Stets R; Vyshnyvetskyy I; Feshchenko Y
Acta Biomed; 2022 May; 93(2):e2022238. PubMed ID: 35545995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
